# EXCELLOS"



### **COMMITTED TO YOUR SUCCESS**

#### PROVIDING DEEPER CHARACTERIZATION TO MEET YOUR DEVELOPMENT NEEDS

Since 2016, Excellos has run a fully operational cGMP manufacturing facility for advanced therapies inside the San Diego Blood Bank, and has developed a number of CT products and services. We offer everything from recruitment of donors, blood and apheresis collections, cell isolation and purification, cell transduction, cell expansion, and final fill and finish under cGMP standards.

Our proprietary Excellos™ 360 deep cell characterization approach addresses variabilities in clinical outcomes by employing Excellos's deep cell characterization approach to address these variabilities by going deeper than typical cell and donor screening to create a comprehensive immune cell profile for each donor, as well as an assessment of the metabolic and effector potential of their cells that sees beyond surface markers.


EXCELLOS"

360

Excellos 360 works to improve the potency of cell-based treatments for reduced clinical response variability, in order to:

- Improve clinical outcomes,
- Lower safety liability by making therapies effective in lower dosages
- Lower the cost of goods associated with cell and gene therapy manufacture.

Excellos 360 will allow you to accelerate the development and production of more effective and accessible cell and immunotherapy treatments.



### **APPLICATIONS WE SUPPORT**

#### CELLULAR STARTING MATERIAL FOR ADVANCED THERAPIES

High-quality cellular material is critical to the development and clinical manufacturing of CAR-T and other immunotherapies. Excellos supports you from development through commercialization with:

- Highly characterized leukopaks from healthy donors with extensive functional characterization for the development of allogeneic CAR-T (RUO and GMP)
- Freshly collected cord blood units (RUO and GMP)
- RUO fresh and cryopreserved cell isolates: PBMCs, T cells, including rare T cell subsets, NK cells and CD34+ stem cells
- Research services, including FACS analysis, advanced functional assays and HLA-Typing

## PRODUCTION OF FEEDER CELLS FOR ADVANCING TUMOR-INFILTRATING LYMPHOCYTE (TIL) THERAPIES

The expansion of TIL products is notoriously difficult. It has been shown that accessory cells in the T cell culture environment can facilitate lymphocyte growth.

To support your TIL rapid expansion protocol, Excellos provides irradiated allogeneic peripheral blood mononuclear cells (PBMCs) from healthy donors for T cell co-culturing. Our PBMCs are irradiated using X-rays at a dosage that retains native costimulatory abilities, but renders them incompetent for replication. Excellos can also perform replication competency testing of feeder cells to provide expedited QA release for clinical and commercial production.

### PROCESS DEVELOPMENT AND cGMP MANUFACTURING FOR REGENERATIVE MEDICINE AND ADVANCED THERAPIES

Excellos has a dedicated Process Development team to support clients in development, tech transfer and optimization of their process. Once locked, Excellos will transfer the process to their state-of-the-art cGMP manufacturing facility for clinical through commercial manufacturing. Services include:

- Donor management
- Apheresis and cord blood collection
- Autologous and allogeneic cell processing
- Production of large cell banks (including master) through isolation, genetic modification, separation and expansion
- CAR-T, CAR-NK, Gamma Delta T cell production
- Technology assessment
- Cryopreservation
- Storage and transport
- Stability

#### **Functional Assays**

- Replication Competency Assay
- T Cell Killing Assay
- Cytokine Release Assays








### **QUALITY ASSURANCE AND REGULATORY AFFAIRS**

## COMPREHENSIVE QUALITY ASSURANCE AND REGULATORY AFFAIRS SUPPORT

Starting materials for cell and gene therapy products fundamentally define their safety and efficacy. Apheresis, cell collection and processing centers must be supported by comprehensive quality oversight systems. Our relationship with the San Diego Blood Bank provides exclusive access to one of the largest and most diverse donor pools available and deep institutional expertise. Relationships with other blood banks further expand our donor pool.

Our comprehensive Quality Assurance and Regulatory Compliance strategy is continuously reviewed by internal audit teams, regulators, and our customers. We put the patient first in our actions and decisions, and work to improve industry standards to drive better patient outcomes.



### **Excellos Incorporated**

1155 Island Avenue San Diego, CA 92101 619.810.5810

info@excellos.com www.excellos.com